Advertisement

Molecular Medicine

, Volume 21, Issue 1, pp 576–583 | Cite as

Pharmacological Targeting of Protease-Activated Receptor 2 Affords Protection from Bleomycin-Induced Pulmonary Fibrosis

  • Cong Lin
  • Jan von der Thüsen
  • Joost Daalhuisen
  • Marieke ten Brink
  • Bruno Crestani
  • Tom van der Poll
  • Keren Borensztajn
  • C. Arnold Spek
Research Article

Abstract

Idiopathic pulmonary fibrosis is the most devastating diffuse fibrosing lung disease that remains refractory to therapy. Despite increasing evidence that protease-activated receptor 2 (PAR-2) contributes to fibrosis, its importance in pulmonary fibrosis is under debate. We addressed whether PAR-2 deficiency persistently reduces bleomycin-induced pulmonary fibrosis or merely delays disease progression and whether pharmacological PAR-2 inhibition limits experimental pulmonary fibrosis. Bleomycin was instilled intranasally into wild-type or PAR-2-deficient mice in the presence/absence of a specific PAR-2 antagonist (P2pal-18S). Pulmonary fibrosis was consistently reduced in PAR-2-deficient mice throughout the fibrotic phase, as evident from reduced Ashcroft scores (29%) and hydroxyproline levels (26%) at d 28. Moreover, P2pal-18S inhibited PAR-2-induced profibrotic responses in both murine and primary human pulmonary fibroblasts (p < 0.05). Once daily treatment with P2pal-18S reduced the severity and extent of fibrotic lesions in lungs of bleomycin-treated wild-type mice but did not further reduce fibrosis in PAR-2-deficient mice. Importantly, P2pal-18S treatment starting even 7 d after the onset of fibrosis limits pulmonary fibrosis as effectively as when treatment was started together with bleomycin instillation. Overall, PAR-2 contributes to the progression of pulmonary fibrosis, and targeting PAR-2 may be a promising therapeutic strategy for treating pulmonary fibrosis.

Notes

Acknowledgments

This work was supported by grant from TiPharma (T1-215-1) and the Netherlands Organization for Scientific Research (016.136.167).

Supplementary material

10020_2015_2101576_MOESM1_ESM.pdf (423 kb)
Supplementary material, approximately 422 KB.

References

  1. 1.
    King TEJr, Pardo A, Selman M. (2011) Idiopathic pulmonary fibrosis. Lancet. 378:1949–61.CrossRefGoogle Scholar
  2. 2.
    Gross TJ, Hunninghake GW. (2001) Idiopathic pulmonary fibrosis. N. Engl. J. Med. 345:517–25.CrossRefGoogle Scholar
  3. 3.
    du Bois RM. (2010) Strategies for treating idiopathic pulmonary fibrosis. Nat. Rev. Drug. Discov. 9:129–40.CrossRefGoogle Scholar
  4. 4.
    Wynn TA. (2011) Integrating mechanisms of pulmonary fibrosis. J. Exp. Med. 208:1339–50.CrossRefGoogle Scholar
  5. 5.
    Crosby LM, Waters CM. (2010) Epithelial repair mechanisms in the lung. Am. J. Physiol. Lung Cell. Mol. Physiol. 298:L715–31.CrossRefGoogle Scholar
  6. 6.
    Coultas DB. (2014) Coagulation disorders and the IPF puzzle. Thorax. 69:203–4.CrossRefGoogle Scholar
  7. 7.
    José RJ, Williams AE, Chambers RC. (2014) Proteinase-activated receptors in fibroproliferative lung disease. Thorax. 69:190–2.CrossRefGoogle Scholar
  8. 8.
    Coughlin SR. (2000) Thrombin signalling and protease-activated receptors. Nature. 407:258–64.CrossRefGoogle Scholar
  9. 9.
    Adams MN, et al. (2011) Structure, function and pathophysiology of protease activated receptors. Pharmacol. Ther. 130:248–82.CrossRefGoogle Scholar
  10. 10.
    Ramachandran R, Noorbakhsh F, Defea K, Hollenberg MD. (2012) Targeting proteinase-activated receptors: therapeutic potential and challenges. Nat. Rev. Drug. Discov. 11:69–86.CrossRefGoogle Scholar
  11. 11.
    Rothmeier AS, Ruf W. (2012) Protease-activated receptor 2 signaling in inflammation. Semin. Immunopathol. 34:133–49.CrossRefGoogle Scholar
  12. 12.
    Borensztajn K, et al. (2008) Factor Xa stimulates proinflammatory and profibrotic responses in fibroblasts via protease-activated receptor-2 activation. Am. J. Pathol. 172:309–20.CrossRefGoogle Scholar
  13. 13.
    Georgy SR, et al. (2012) Proteinase-activated receptor-2 is required for normal osteoblast and osteoclast differentiation during skeletal growth and repair. Bone. 50:704–12.CrossRefGoogle Scholar
  14. 14.
    Luo W, Wang Y, Reiser G. (2007) Protease-activated receptors in the brain: receptor expression, activation, and functions in neurodegeneration and neuroprotection. Brain Res. Rev. 56:331–45.CrossRefGoogle Scholar
  15. 15.
    Gorelick F. (2007) Pancreatic protease-activated receptors: friend and foe. Gut. 56:901–2.CrossRefGoogle Scholar
  16. 16.
    Wygrecka M, et al. (2011) Role of protease-activated receptor-2 in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 183:1703–14.CrossRefGoogle Scholar
  17. 17.
    Wygrecka M, et al. (2013) Mast cells and fibroblasts work in concert to aggravate pulmonary fibrosis: role of transmembrane SCF and the PAR-2/PKC-α/Raf-1/p44/42 signaling pathway. Am. J. Pathol. 182:2094–108.CrossRefGoogle Scholar
  18. 18.
    Park YS, et al. (2013) Clinical implication of protease-activated receptor-2 in idiopathic pulmonary fibrosis. Respir. Med. 107:256–62.CrossRefGoogle Scholar
  19. 19.
    Borensztajn K, et al. (2010) Protease-activated receptor-2 induces myofibroblast differentiation and tissue factor up-regulation during bleomycin-induced lung injury: potential role in pulmonary fibrosis. Am. J. Pathol. 177:2753–64.CrossRefGoogle Scholar
  20. 20.
    Kalayarasan S, Sriram N, Soumyakrishnan S, Sudhandiran G. (2013) Diallylsulfide attenuates excessive collagen production and apoptosis in a rat model of bleomycin induced pulmonary fibrosis through the involvement of protease activated receptor-2. Toxicol. Appl. Pharmacol. 271:184–95.CrossRefGoogle Scholar
  21. 21.
    Soumyakrishnan S, et al. (2014) Daidzein exhibits anti-fibrotic effect by reducing the expressions of Proteinase activated receptor 2 and TGFβ1/Smad mediated inflammation and apoptosis in bleomycin-induced experimental pulmonary fibrosis. Biochimie. 103:23–36.CrossRefGoogle Scholar
  22. 22.
    Su X, Matthay MA. (2009) Role of protease activated receptor 2 in experimental acute lung injury and lung fibrosis. Anat. Rec. 292:580–6.CrossRefGoogle Scholar
  23. 23.
    Park YS, Yoo CG. (2013) The clinical assessment of protease-activated receptor-2 expression in inflammatory cells from peripheral blood and bronchoalveolar lavage fluid in idiopathic pulmonary fibrosis. Tuberc. Respir. Dis. 74:264–8.CrossRefGoogle Scholar
  24. 24.
    Matěj R, Olejár T. (2012). The role of proteinase-activated receptor-2 in idiopathic pulmonary fibrosis: is there really novel therapeutic potential here? Am. J. Respir. Crit. Care Med. 185:458–9.CrossRefGoogle Scholar
  25. 25.
    Wang X, et al. (2003) Necrotic cell death in response to oxidant stress involves the activation of the apoptogenic caspase-8/bid pathway. J. Biol. Chem. 278:29184–91.CrossRefGoogle Scholar
  26. 26.
    Weyrich AS, et al. (1996) Activated platelets signal chemokine synthesis by human monocytes. J. Clin. Invest. 97:1525–34.CrossRefGoogle Scholar
  27. 27.
    Sevigny LM, et al. (2011) Interdicting protease-activated receptor-2-driven inflammation with cell-penetrating pepducins. Proc. Natl. Acad. Sci. U. S. A. 108:8491–6.CrossRefGoogle Scholar
  28. 28.
    Lin C, et al. (2014) Targeting protease activated receptor-1 with P1pal-12 limits bleomycin-induced pulmonary fibrosis. Thorax. 69:152–60.CrossRefGoogle Scholar
  29. 29.
    Ashcroft T, Simpson JM, Timbrell V. (1988) Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J. Clin. Pathol. 41:467–70.CrossRefGoogle Scholar
  30. 30.
    Lin C, et al. (2015) Protease-activated receptor (PAR)-2 is required for PAR-1 signaling in pulmonary fibrosis. J. Cell. Mol. Med. 19:1346–56.CrossRefGoogle Scholar
  31. 31.
    Idell S, et al. (1987) Bronchoalveolar lavage procoagulant activity in bleomycin-induced lung injury in marmosets. Characterization and relationship to fibrin deposition and fibrosis. Am. Rev. Respir. Dis. 136:124–33.CrossRefGoogle Scholar
  32. 32.
    Cutroneo KR, White SL, Phan SH, Ehrlich HP. (2007) Therapies for bleomycin induced lung fibrosis through regulation of TGF-beta1 induced collagen gene expression. J. Cell. Physiol. 211:585–9.CrossRefGoogle Scholar
  33. 33.
    Moore BB, Hogaboam CM. (2008) Murine models of pulmonary fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 294: L152–60.CrossRefGoogle Scholar
  34. 34.
    Materazzi S, et al. (2007) Analysis of protease-activated receptor-1 and -2 in human scar formation. J. Pathol. 212:440–9.CrossRefGoogle Scholar
  35. 35.
    Borensztajn K, von der Thüsen JH, Peppelenbosch MP, Spek CA. (2010) The coagulation factor Xa/protease activated receptor-2 axis in the progression of liver fibrosis: a multifaceted paradigm. J. Cell. Mol. Med. 14:143–53.CrossRefGoogle Scholar
  36. 36.
    Chung H, Ramachandran R, Hollenberg MD, Muruve DA. (2013) Proteinase-activated receptor-2 transactivation of epidermal growth factor receptor and transforming growth factor-β receptor signaling pathways contributes to renal fibrosis. J. Biol. Chem. 288:37319–31.CrossRefGoogle Scholar
  37. 37.
    Mouratis MA, Aidinis V. (2011) Modeling pulmonary fibrosis with bleomycin. Curr. Opin. Pulm. Med. 17:355–61.CrossRefGoogle Scholar
  38. 38.
    Pini A, et al. (2010) Prevention of bleomycin-induced pulmonary fibrosis by a novel antifibrotic peptide with relaxin-like activity. J. Pharmacol. Exp. Ther.335:589–99.CrossRefGoogle Scholar
  39. 39.
    De Candia E. (2012) Mechanisms of platelet activation by thrombin: a short history. Thromb. Res. 129:250–6CrossRefGoogle Scholar
  40. 40.
    Ostrowska E, Sokolova E, Reiser G. (2007) PAR-2 activation and LPS synergistically enhance inflammatory signaling in airway epithelial cells by raising PAR expression level and interleukin-8 release. Am. J. Physiol. Lung Cell. Mol. Physiol. 293: L1208–18.CrossRefGoogle Scholar
  41. 41.
    Kida Y, Inoue H, Shimizu T, Kuwano K. (2007) Serratia marcescens serralysin induces inflammatory responses through protease-activated receptor 2. Infect. Immun. 75:164–74.CrossRefGoogle Scholar
  42. 42.
    Nhu QM, Shirey KA, Pennini ME, Stiltz J, Vogel SN. (2012) Proteinase-activated receptor 2 activation promotes an anti-inflammatory and alternatively activated phenotype in LPS-stimulated murine macrophages. Innate Immun. 18:193–203.CrossRefGoogle Scholar
  43. 43.
    Nhu QM, et al. (2010) Novel signaling interactions between proteinase-activated receptor 2 and Toll-like receptors in vitro and in vivo. Mucosal Immunol. 3:29–39.CrossRefGoogle Scholar
  44. 44.
    Antoniak S, et al. (2013) Protease activated receptor-2 contributes to heart failure. PLoS One 8:e81733.CrossRefGoogle Scholar
  45. 45.
    Kwapiszewska G, et al. (2012) PAR-2 inhibition reverses experimental pulmonary hypertension. Circ. Res. 110:1179–91.CrossRefGoogle Scholar
  46. 46.
    Michael ES, Kuliopulos A, Covic L, Steer ML, Perides G. (2013) Pharmacological inhibition of PAR2 with the pepducin P2pal-18S protects mice against acute experimental biliary pancreatitis. Am. J. Physiol. Gastrointest. Liver Physiol. 304: G516–26.CrossRefGoogle Scholar
  47. 47.
    Boileau C, et al. (2010) Oral treatment with a Brachystemma calycinum D don plant extract reduces disease symptoms and the development of cartilage lesions in experimental dog osteoarthritis: inhibition of protease-activated receptor 2. Ann. Rheum. Dis. 69:1179–84.CrossRefGoogle Scholar

Copyright information

© The Author(s) 2015

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.

The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit (https://doi.org/creativecommons.org/licenses/by-nc-nd/4.0/)

Authors and Affiliations

  • Cong Lin
    • 1
  • Jan von der Thüsen
    • 2
  • Joost Daalhuisen
    • 1
  • Marieke ten Brink
    • 1
  • Bruno Crestani
    • 3
  • Tom van der Poll
    • 1
  • Keren Borensztajn
    • 1
    • 4
    • 5
  • C. Arnold Spek
    • 1
  1. 1.Center for Experimental and Molecular MedicineAcademic Medical CenterAmsterdamThe Netherlands
  2. 2.Department of PathologyErasmus Medical CentreRotterdamThe Netherlands
  3. 3.Assistance Publique-Hôpitaux de Paris, Department of Pulmonology A, Reference Center for Rare Lung DiseasesBichat-Claude Bernard University HospitalParisFrance
  4. 4.Medical School Xavier BichatInserm UMR1152ParisFrance
  5. 5.Département Hospitalo-universtaire FIRE (Fibrosis, Inflammation and Remodeling) and LabEx InflamexParisFrance

Personalised recommendations